Post navigation Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative PainCell Culture Vessels Market worth $8.03 billion by 2030 | MarketsandMarkets™